This selective toxicity aligns with the mechanism of TROP2-targeted ADCs and is backed by preclinical and clinical data from other tumor types (Goldenberg & Sharkey 2019; Pavone et al. 2021; Zhang et al. 2025a, b). The gene discussed is TACSTD2; the disease is neoplasm.